Active pulmonary tuberculosis: Role for amikacin in early treatment.

[1]  D. Mitchison,et al.  The early bactericidal activity of drugs in patients with pulmonary tuberculosis. , 2015, The American review of respiratory disease.

[2]  D. Che,et al.  [Epidemiology of tuberculosis]. , 2012, La Revue du praticien.

[3]  D. Che,et al.  [Epidemiology of tuberculosis in France in 2008]. , 2011, Medecine et maladies infectieuses.

[4]  A. van Belkum,et al.  Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis. , 2010, The Journal of antimicrobial chemotherapy.

[5]  J. Chevillotte.  Surveiller et prévenir les infections associées aux soins , 2010 .

[6]  T. Udou.  Comparative Evaluation of the In Vitro Antimycobacterial Activities of Six Aminoglycoside Antibiotics Using an Agar Dilution Method , 2006, Journal of chemotherapy.

[7]  D. Curran‐Everett,et al.  Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  R. Altena.  Hearing loss and nephrotoxicity treatment in patients with in long-term aminoglycoside tuberculosis , 2002 .

[9]  P. Brouqui,et al.  Clinical and microbiological efficacy of adjunctive salvage therapy with inhaled aminoglycosides in a patient with refractory cavitary pulmonary tuberculosis. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  M. Iseman,et al.  Some healthy skepticism about inhaled therapy for tuberculosis. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  D. Mitchison,et al.  The early bactericidal activity of amikacin in pulmonary tuberculosis. , 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[12]  J. Justman,et al.  Factors influencing time to sputum conversion among patients with smear-positive pulmonary tuberculosis. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  C. Chan,et al.  In-vitro activities of aminoglycoside-aminocyclitols against mycobacteria. , 1997, The Journal of antimicrobial chemotherapy.

[14]  Pulmonary Infections.  Treatment of Tuberculosis and Tuberculosis Infection in Adults and Children , 1998 .

[15]  D. Snider,et al.  Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. , 1994, American journal of respiratory and critical care medicine.

[16]  L. Gabbasova,et al.  Global tuberculosis report (2014) , 2014 .

[17]  C-L. Hsu,et al.  Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis. , 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[18]  P. D. de Jager,et al.  Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. , 2002, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[19]  L. Sacks,et al.  Adjunctive salvage therapy with inhaled aminoglycosides for patients with persistent smear-positive pulmonary tuberculosis. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.